Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Codeine + pseudoephedrine** is an oral combination drug comprised of codeine, an opioid antitussive, and pseudoephedrine, a sympathomimetic amine decongestant. Codeine acts centrally on the medullary cough center as a mu-opioid receptor agonist, suppressing the cough reflex. Pseudoephedrine exerts its decongestant effect by acting primarily as an agonist at alpha-1 and alpha-2 adrenergic receptors in the nasal mucosa, inducing vasoconstriction and reducing swelling and congestion. This combination is used for symptomatic relief of cough and nasal congestion in conditions such as the common cold or allergies. It is available as a prescription medicine and is generally supplied in oral syrup formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on codeine + pseudoephedrine.